INTRODUCTION
Drug-eluting stents have shown great efficacy in the reduction of restenosis as compared with bare-metal stent (BMS) by suppressing neointimal growth [1] [2] [3] [4] [5] . The second-generation Taxus Liberte stent (paclitaxeleluting stent, Boston Scientific Co., Natick, MA, USA) evolved from the Taxus Express stent in order to enhance stent deliverability and uniform drug delivery.
However, there is little comparative data from realworld daily clinical practice with these stents. The aim of this study was to compare angiographic and clinical outcomes between the new Taxus Liberte stent and the old Taxus Express stent in real-world clinical practice.
METHODS

Device description
The Taxus Liberte-SR stent consists of a balloonexpandable Liberte stent with a polymer coating containing 1 μg/mm 2 of paclitaxel in a slow-release formulation. Drug dosing and release kinetics are identical to that of the Taxus Express-SR stent. Both stents are made from 316 L stainless steel, but the Liberte platform has a more uniform strut pattern and thinner struts (0.097 mm) than the Express platform (0.132 mm) [6] . 
Study population
Procedures and medications
Percutaneous coronary intervention (PCI) was performed using standard techniques. All patients received aspirin 325 mg orally and a loading dose of 300 mg of clopidogrel before coronary angiography (CAG) or after PCI in emergency cases. After PCI, the patients were treated routinely with aspirin 100 mg/day, clopidogrel 75 mg/day, and/or cilostazol 200 mg/day at the operator's discretion. The patients were advised to maintain life-long aspirin therapy. The duration of taking clopidogrel was at the operator's discretion, which depended on the complexity of the lesion and procedure.
Quantitative coronary analysis
Intracoronary nitroglycerin (0.2 mg) was administered before and after each intervention to achieve maximal dilatation. Quantitative CAG was performed immediately before and after stenting by an experienced technician who was blinded to the type of stent deployed. Angiographic measurements included proximal and distal reference, minimum lumen diameter (MLD), percentage of lesion diameter stenosis, and lesion length. Acute gain was measured and defined as the difference between the MLD after stent deployment and baseline MLD. Late lumen loss was calculated as the difference in MLD immediately after the procedure and at angiographic follow-up. All measurements were performed for both the stented segment (in-stent) and 5-mm proximal and distal margins of the stented segment (in-segment). Quantitative coronary angiographic analysis was performed using the computerassisted automated edge detection method (Centricity, Cardiology CA1000, GE Healthcare, Milwaukee, WI, USA) in the angiography analysis core laboratory at Yeungnam University Medical Center.
Study outcomes and definitions
The study outcome was a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), ischemia-driven target vessel revascularization (TVR), and stent thrombosis (ST). MI was defined as a recurrent ischemic symptom and/ or ECG change with creatine kinase-myocardial band fraction elevation up to twice the upper limit of normal. Ischemia-driven TVR was defined as emergency or elective CABG or repeat PCI in the target vessel for chest pain or a positive test for ischemia [7] . [8] . Angiographic restenosis was defined as a ≥ 50% diameter stenosis within the target lesion. Death was regarded as cardiac except for those of proven non-cardiac origin.
Follow-up
Clinical follow-up was performed at 30 days, 3 months, 6 months, and 1 year after PCI according to our routine practice. Angiographic follow-up was recommended in all living patients and performed at 9 to 12 months after PCI. The 1-year clinical follow-up data were collected by chart review or telephone interview.
Statistical analysis
Data are expressed as means ± standard deviation (SD) for continuous variables, and as frequencies for categorical variables. Categorical data were analyzed with the chi-square test and continuous variables were evaluated with Student's t tests. To decrease the effect of selection biases and potential confounding, propensity score matching was performed on patient baseline characteristics [9] . For the entire cohort comparison, a separate propensity score for Taxus Liberte versus Taxus Express was derived. The following variables were used to calculate the propensity score: age, sex, hypertension, current smoking, diabetes mellitus, dyslipidemia, previous PCI, previous CABG, renal failure, left ventricular ejection fraction, clinical diagnosis, disease vessel number, medications, target vessel, type of lesion, bifurcation lesion, procedure on infarct related artery, procedure-related MI, stent number, mean stent diameter, total stent length, maximal inflation pressure, and post-stenting adjunctive balloon inf lation. After all of the propensity score matches were performed, angiographic and clinical outcomes were compared. The p values < 0.05 were considered to indicate statistical significance. Data were analyzed using the SPSS for Windows version 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics and angiographic outcomes
Baseline characteristics (Table 1) , angiographic and procedural outcomes (Table 2) , and quantitative coronary angiography outcomes in (Table 3) Fig. 1 ; there was no significant difference between the groups (p = 0.808).
Clinical outcomes after propensity matching
DISCUSSION
The main findings of this study suggest that both Taxus stents, with the same polymer and the same drug on different stent designs, had similarly good 1-year clinical and angiographic outcomes in real-world use. The Taxus Express stent shows polymer-regulated delivery of paclitaxel from the Boston Scientific/Medinol NIR and Boston Scientific EXPRESS stent platforms [10] . The Taxus stent consists of three components: 1) the metallic stent, 2) paclitaxel, an antiproliferative
agent that inhibits neointimal formation, and 3) the polymer, a drug-carrier vehicle [11, 12] . The Taxus Express stent was approved in released. Taxus stents have been shown to be superior to BMSs in reducing restenosis rates and target lesion revascularization [4, 5, [13] [14] [15] . Stent design is recognized as an important determinant of stent performance [16] . Strut thickness, [19] . The latter study focused mainly on stable angina patients (52.8% in Taxus Express vs. 60.2% in Taxus Liberte; p = 0.0015); however, our study mostly included patients with unstable angina and MI (65.9% in Taxus Express vs. 68% in Taxus Liberte). The MACE rate in the Taxus ATLAS study was 12.3% in the Taxus Express group and 12.5% in the Taxus Liberte group, driven mainly by an increased TVR rate (8.9% in Taxus Express vs. 9.2% in Taxus Liberte; p = 0.833). Our study showed that the MACE rate was 4.05% in each group and TVR rate was 2.31% in Taxus Express and 1.16% in Taxus Liberte (p = 0.684). The reason for the better results is unknown. However, longer treatment duration with the dual antiplatelet regimen may be a cause. In the Taxus ATLAS study, the incidence of the dual antiplatelet regimen at 9 months was only Values are presented as number (%) or mean ± SD. a According to the American Heart Association and/or American College of Cardiology.
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62.6% in the Taxus Liberte and 54.2% in the Taxus Express patients. In our study, although the duration of dual antiplatelet was at the operator's discretion, the mean duration was 12.7 months in the Liberte group and 13.2 months in the Express group. Several previous studies have demonstrated that thinner strut stents are associated with a significant reduction of clinical and angiographic restenosis as compared with thicker-strut stents [17, 18, 20] . Another study comparing two Taxus stents, the Taxus ATLAS small vessel (2.25 mm stent) and long lesion (38 mm stent) multicenter studies, showed that the Taxus Liberte stent improved MACE rates as compared with the earlier Taxus Express stent in both small vessels and long lesions [6] .
Although the mechanism for this improved outcome remains unclear, thinner strut thickness and the more uniform and denser distribution of struts in the Taxus Liberte may be related to reduced deep vessel injury during implantation or improved healing, beyond simply improving deliverability [17] .
Our study is a real-world clinical study, comparing the new-generation Taxus Liberte stent with the Taxus Express. At first, we thought the later-developed The Korean Journal of Internal Medicine Vol. 28, No. 1, January 2013 stent (Taxus Liberte) may have better clinical and angiographic outcomes than the earlier version (Taxus Express). However, our study did not show any clinical difference at 1 year. First, this may be due to the relatively short follow-up duration and a longer follow-up might reveal differences. Second, the potential impact of reduced strut thickness on late lumen loss may be overcome by the relative impact of drug and polymer. This study has some limitations. First, the study population was relatively small. Second, this was a retrospective, observational, non-randomized study. However, we performed propensity score matching to minimize these shortcomings. Third, after propensity score matching, 69 patients in the Liberte group and 99 patients in the Express group were excluded. Exclusion of such large numbers of patients may weaken the representativeness of the target population. Fourth, as we mentioned, there was no follow-up beyond 1 year. With further long-term follow-up data, we cannot exclude the possibility that the final results may be different. Fifth, we did not use imaging modalities, such as intravascular ultrasound, in most patients to more precisely determine differences and the underlying mechanisms between the two stents.
In conclusion, in this real-world study of experi- Values are presented as number (%). MACE, major adverse cardiac events; MI, myocardial infarction; TVR, target vessel revascularization. 
